GlassScriptPhysician profile
Jake Trahan
NPI 1497141824
$8,969.64
in general payments reported to CMS, 2019-2025
29 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 80% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $147 · 2021: $2,300 · 2022: $558 · 2023: $1,146 · 2024: $2,266 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,879 · Travel and Lodging: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.09 |
| Travel and Lodging | $2,349.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,068.27 | 2019-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $1,347.71 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Relievant Medsystems, INC. | $1,302.28 | 2021-2022 | |
| Boston Scientific Corporation | $546.56 | 2021-2024 | |
| Spinal Simplicity, LLC | $248.18 | 2023-2024 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $192.49 | 2019 | |
| Nevro Corp. | $158.87 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $146.77 | 2020-2024 | Belbuca |
| Spr Therapeutics, INC | $145.55 | 2021-2025 | Sprint Pns System |
| Biotronik Nro, INC. | $135.55 | 2025 | Prospera |
| Stryker Corporation | $105.86 | 2023 | Omnicurve, Spinejack, Avaflex |
| Abbvie INC. | $77.75 | 2022-2024 | Botox |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.70 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $49.33 | 2022 | |
| Biotronik INC. | $43.99 | 2025 | Amvia Edge |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $41.81 | 2024 | Movantik |
| Virtus Pharmaceuticals LLC | $33.86 | 2023 | Levorphanol Tartrate |
| Scilex Pharmaceuticals INC. | $33.57 | 2023-2024 | Ztlido |
| Nalu Medical, INC. | $32.85 | 2021-2024 | Nalu Neurostimulation System |
| Biohaven Pharmaceuticals, INC. | $31.16 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $25.37 | 2023 | Dysport |
| Averitas Pharma INC. | $20.68 | 2023 | Qutenza |
| Alfasigma USA, INC. | $19.94 | 2022 | |
| Horizon Therapeutics Plc | $17.69 | 2022 | |
| Baudax Bio INC. | $17.29 | 2020 | |
| Redhill Biopharma INC. | $16.49 | 2021 | |
| Stimwave Technologies Incorporated | $15.57 | 2021 | |
| Convatec INC. | $15.06 | 2024 | |
| Si-Bone, INC. | $10.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Trahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.